Laurus Labs Ltd. · NSE:LAURUSLABS
Laurus Labs — Q1 FY2026 Earnings Presentation
24 slides from Laurus Labs's earnings presentation, Jul 25, 2025
Slide 1: Exchange filing cover letter
July 25, 2025 To To The Corporate Relations Department The Listing Department BSE Limited National Stock Exchange of India Ltd., Phiroze Jeejeebhoy Towers, Exchange Plaza, Dalal Street, Bandra Kurla Complex, Bandra (E), Mumbai – 400 001 Mumbai – 400 051 Code: 540222 Code: LAURUSLABS Dear Sir / Madam
Slide 2: Q1-FY 2026 Financial Results
Q1-FY 2026 Financial Results 25/07/2025 © 2025 Laurus Labs Ltd.
Slide 3: Safe Harbor Statement
Safe Harbor Statement This presentation contains statements that constitute “forward looking statements” including and without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to our future business developments and economic performance. W
Slide 4: Agenda
Agenda 1 Q1 FY 2026 Corporate Overview 2 Q1 FY 2026 Financial Overview 3 Q1 FY 2026 Business Review & Strategy © 2025 Laurus Labs Ltd. Q1 - FY26 Results Presentation 25/07/2025 3
Slide 5: Corporate Overview
1 Corporate Overview Q1 FY 2026 4
Slide 6: Executive Summary
Executive Summary • Strong performance continued in Q1; ₹ 1,570 Cr Revenues and 31% revenues growth • Attractive market opportunities favoring robust CDMO momentum, expanding collaboration in complex API and growth in Generics • ₹ 389 Cr EBITDA resulted in a margin of 24.8%, improving by 10.5% pts,
Slide 7: Continued recovery in asset turnover levels and resilient margins
Continued recovery in asset turnover levels and resilient margins • Continued recovery in asset turns at expanded gross (~6 Quarters) 1.5x margins since mid-FY25 following significant CDMO - Long lead times for - High value CDMO project deliveries 54% Complex CDMO project deliveries and projects ram
Slide 8: Ongoing strategic investment to drive growth
Ongoing strategic investment to drive growth • >85% Growth CAPEX across API / CDMO CAPEX Project Mix Phase-wise Split of Investments portfolio supported by integrated Drug product approach 8% 23% • Groundbreaking of new Gene/ADC facility 33% (Hyderabad), and Microbial fermentation ~ ₹ 3,400 Cr 2 fac
Slide 9: Integrated 'D & M' platform with unique capabilities to support Global customers
Integrated ‘D & M’ platform with unique capabilities to support Global customers R&D center Small Molecules R&D with Kilo lab, Hyderabad Unit 1 & 3, Vizag 3600 KL DS/DP Development 1 API/DS Manufacturing 1 2 3 4 5 6 7900 KL Reactors volumes New R&D, Hyderabad Unit 5, Vizag 161 KL DS Development 1 DS
Slide 10: Financial Overview
2 Financial Overview Q1 FY 2026 9
Slide 11: 1Q FY26: Strong performance
1Q FY26: Strong performance 1Q FY26 Financial Summary Comments [₹ Crore] 4Q FY25 1Q FY26 1Q FY25 Y-o-Y Q-o-Q • Revenues : ₹ 1,570 Cr, increased 31% primarily driven by robust CDMO performance while growth in generic FDF partly offset by lower API business Revenues 1,720 1,570 1,195 31% -9% • Gross M
Slide 12: Summary Quarter Performance: Acceleration in growth momentum
Summary Quarter Performance: Acceleration in growth momentum EBITDA & Gross Profit Margins Revenues [₹ Cr] 900 [₹ Cr] 56.9% 59.4% GPM 55.1% 55.2% 58.0% 54.3% 54.5% 800 52.5% 1,720 700 49.8% 48.0% 1,570 600 1,440 1,415 27.7% 38.0% 24.8% 500 1,224 1,195 1,195 1,224 OPM 400 18.0% 20.1% 28.0% 300 15.4%
Slide 13: Business Review & Strategy
3 Business Review & Strategy Q1 FY 2026 12
Slide 14: 1Q FY26: Strong CDMO momentum supported by Generic FDF
1Q FY26: Strong CDMO momentum supported by Generic FDF 1Q FY26 Divisional Revenue Performance 1Q FY26 Divisional Mix [₹ Crore] 4Q FY25 1Q FY26 1Q FY25 Y-o-Y Q-o-Q CDMO 490 522 257 103% 7% 26% CDMO 33% Small molecules 461 493 214 130% 7% 31% / +12% over last year Bio 29 29 43 -33% 0% Generics 67% / -
Slide 15: CDMO – Small molecules: Strong demand for complex offerings continued
CDMO – Small molecules: Strong demand for complex offerings continued Revenue Growth Comments [₹ Cr] Y-o-Y ▲ 130% • Continued strong growth >130% driven by several mid-to-late Q-o-Q ▲ 7% stage NCE deliveries and ramp up from new manufacturing assets • Sustained demand in high-value/complex small mol
Slide 16: BIO – Focus continues on building robust pipeline
BIO – Focus continues on building robust pipeline Revenue Growth Comments [₹ Cr] Y-o-Y ▼ 33% • Divisional revenues impacted by Customer specific issue and Q-o-Q ▲ 0% pricing challenge. Focus continued on building strong and diversified pipeline • Enzymatic chemistry platform across small molecule cl
Slide 17: GENERICS – Growth led by FDF, Portfolio expansion efforts continues
GENERICS – Growth led by FDF, Portfolio expansion efforts continues Revenue Growth Comments [₹ Cr] Y-o-Y ▲ 12% • Growth across both ARV & Developed market portfolio mainly Q-o-Q ▼ 15% within FDF. Planned capacity availability to support full year API 1,230 business on track 1,048 938 967 885 • Reven
Slide 18: Other Updates
Other Updates KRKA joint venture1 • Commercial FDF capacity Groundbreaking ceremony of Finished formulation manufacturing facility in Hyderabad at 19 acres site • Invested ₹ 215 Cr in JV (incl. Laurus ₹ 105 Cr and KrKa ₹ 110 Cr) in FY25. Committed to invest over ₹ 500 Cr in initial phase From L to R
Slide 19: Cell and Gene therapy - Updates
Cell and Gene therapy - Updates Cell therapy Gene therapy • NexCAR19 Continued demand > 350 infusions as on June’25. • Break ground on new dedicated Gene/Anti-body Drug Successful infusion for CD-19 Pediatric Trial (Phase II) Conjugates R&D and manufacturing facility in Genome valley Hyderabad (>650
Slide 20: R&D platform: Advancing Sustainable technology and Capability extension
R&D platform : Advancing Sustainable technology and Capability extension Significant Updates • Solidifying position on Flow/Bio-catalysis platform. Executed ton-level >75 R&D project* supported in FY25 project utilizing proprietary designed flow reactors at high temp/pressure • CDMO R&D facility ope
Slide 21: Maintain the Highest Global standard Quality systems
Maintain the Highest Global standard Quality systems “One Quality Standard for all Markets” 1300+ Quality audits & Inspection Global Customers, Regulatory Last US FDA inspection Authorities since inception Key Key Regulatory # audits (since Date EIR Status Facilities Certifications inception) 54 Ins
Slide 22: Appendix
Appendix Pinus Labs
Slide 23: Earnings call details
Earnings call details Laurus Labs Results Conference Call to be held on Friday, 25 July 2025 at 5:00 PM IST Dial – In – Details Universal Dial-In +91 22 6280 1384 Click below to Express Join with India Local access Number +91 22 7115 8285 Diamond Pass Singapore +800 1012045 Click here to register Ho
Slide 24: Additional Information
Additional Information Laurus Labs is a research-driven pharmaceutical and biotechnology company committed to improving global health. It holds a leadership position in developing and manufacturing select Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms (FDF) across anti-retroviral